A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical specialising in precision cancer treatment.

In a London Stock Exchange announcement, GSK confirmed its acquisition of IDRx for $1 billion, with an additional $150 million pending regulatory approval.